From the Children's Healthcare of Atlanta.
Department of Pediatrics, Morehouse School of Medicine.
Pediatr Infect Dis J. 2023 Mar 1;42(3):e64-e69. doi: 10.1097/INF.0000000000003801. Epub 2022 Feb 15.
Multisystem inflammatory syndrome in children (MIS-C) rarely involves delayed giant coronary aneurysms, multiple readmissions or occurrence after COVID-19 vaccination.
We describe a child with all 3 of these unusual features. We discuss his clinical presentation, medical management, review of the current literature and CDC guidance recommendations regarding further vaccinations.
A 5-year-old boy had onset of MIS-C symptoms 55 days after COVID-19 illness and 15 days after receiving his first BNT162b2 COVID-19 vaccination. He was admitted 3 times for MIS-C, and twice after his steroid dose was tapered. On his initial admission, he was given intravenous immunoglobulin and steroids. During his second admission, new, moderate coronary dilation was noted, and he was treated with intravenous immunoglobulin and steroids. At his last admission, worsening coronary dilation was noted, and he was treated with infliximab and steroids. During follow-up, he had improvement in his coronary artery dilatation. However, his inflammatory markers increased after steroid wean, and his steroid taper was further extended, after which time his inflammatory markers improved. This is the only such reported case of a patient who was admitted 3 times for MIS-C complications after COVID-19 vaccination.
MIS-C rarely involves delayed giant coronary aneurysms, multiple readmissions, or occurrence after COVID-19 vaccination. Whether our patient's COVID-19 vaccine 6 weeks after COVID-19 illness contributed to his MIS-C is unknown. After consultation with the CDC-funded Clinical Immunization Safety Assessment Project, the patient's care team decided against further COVID-19 vaccination until at least 3 months post normalization of inflammatory markers.
儿童多系统炎症综合征(MIS-C)很少涉及延迟性巨大冠状动脉瘤、多次再入院或 COVID-19 疫苗接种后发生。
我们描述了一例具有这 3 种罕见特征的患儿。我们讨论了他的临床表现、医疗管理,回顾了目前的文献以及美国疾病控制与预防中心(CDC)关于进一步接种疫苗的指导建议。
一名 5 岁男孩在 COVID-19 发病后 55 天和接种第一剂 BNT162b2 COVID-19 疫苗后 15 天出现 MIS-C 症状。他因 MIS-C 入院 3 次,且在类固醇剂量减少后两次入院。入院时,他接受了静脉注射免疫球蛋白和类固醇治疗。第二次入院时,发现新的中度冠状动脉扩张,给予静脉注射免疫球蛋白和类固醇治疗。最后一次入院时,发现冠状动脉扩张恶化,给予英夫利昔单抗和类固醇治疗。随访期间,他的冠状动脉扩张有所改善。然而,在类固醇减量后炎症标志物增加,进一步延长了类固醇减量时间,之后炎症标志物改善。这是唯一一例报道的 COVID-19 疫苗接种后因 MIS-C 并发症入院 3 次的患者。
MIS-C 很少涉及延迟性巨大冠状动脉瘤、多次再入院或 COVID-19 疫苗接种后发生。患者 COVID-19 疫苗接种是在 COVID-19 发病后 6 周进行的,是否导致了他的 MIS-C 尚不清楚。在与 CDC 资助的临床免疫接种安全性评估项目咨询后,患者的治疗团队决定在炎症标志物恢复正常至少 3 个月后,不再进行 COVID-19 疫苗接种。